ClinicalTrials.gg
Status unknownNCT04418505COVIDLightUpdated Jun 14, 2021

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

An interventional study of Vielight RX Plus in COVID-19, sponsored by Vielight Inc.. Status unknown at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Vielight Inc. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
394th of 1,322
295 · median 92
Started
2020
with 817 others
No phase
428 of 1,860
22 open now
Registered
412th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 394th largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 428 with no phase, and was the 412th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to obtain data on the efficacy of the Vielight RX Plus in decreasing time to recovery of symptoms in subjects with COVID-19. The study will be conducted among COVID-19 positive subjects at home in self-isolation via electronic data collection (EDC). There will be no physical contact between the subjects and the Qualified Investigator (QI) or other study staff. This study aims to demonstrate that the Vielight RX Plus is a useful adjunct to standard of care (SOC). We hypothesize that the Vielight RX Plus will accelerate recovery and reduce viral infection severity.

Read the detailed description

This study is conducted entirely online. At no point will study staff be in direct contact with participants. The study will be managed by an independent clinical research organization (CRO), supporting a Qualified Investigator (QI). Vielight Inc will supply the RX Plus devices free of charge and will sponsor the study.

Potential participants will be prompted to complete an online screening form if they are interested in participating. During the screening, the potential participant will be asked to upload a copy of their positive COVID-19 infection confirmation report and a valid ID. If the potential subject qualifies for the study, by statisfying all inclusion and exclusion criteria, the potential participant will then be prompted to complete an electronic informed consent form (ICF) via the electronic data collection (EDC) platform and will be enrolled into the study.

This is a 30-day, prospective, randomized study, with no blinding. 280 participants will be randomized into two groups: Group 1: Standard of Care; Group 2: Standard of Care + Vielight RX Plus treatment. In Group 2, the Vielight RX Plus will be administered for 20 minutes twice a day, separated by at least 6 hours for the first 5 days. For the subsequent 25 days, treatment will be once per day. The Vielight RX Plus will be positioned over the upper most part of the breastbone to stimulate the thymus gland and within one nostril.

During each of the 30-days, participants will be asked to complete a questionnaire to assess respiratory symptom severity, and log a daily dairy as well as oxygen saturation level (using a portable oximeter).

The primary measure is time to overall recovery in days.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • SARS-CoV-2
  • Photobiomodulation
  • Low level light therapy
  • PBM
  • Red light
  • Near-infrared light
  • At-home treatment
  • Remote
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of COVID-19 infection
  • Experiencing moderate to severe respiratory symptoms
  • Between 18-65 years of age

Exclusion criteria

Exclusion Criteria:

  • Need for hospitalization at the time of diagnosis
  • Current need for supplemental oxygen or positive pressure support and/or has required supplemental oxygen or positive pressure support for >or= 24 hours
  • >10 days since symptom onset
  • Diagnosis of (COPD)
  • Pregnant
  • Positive for Virus (HCV), Virus (HBV) or
  • Inability to electronically complete study questionnaires in English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
295 participants (actual)

Study arms

  • No intervention
    Standard of Care

    This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.

  • Experimental
    Standard of Care + Vielight RX Plus Treatment

    The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.

    Device: Vielight RX Plus

Interventions

  • DeviceVielight RX Plus

    The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.

06

What researchers measure

Primary outcomes

  1. Time to recovery

    Time frame: 30 days

Secondary outcomes

  1. Time to elimination of COVID-19 related symptoms

    Time frame: 30 days

  2. Mean number of days with mild COVID-19 related symptoms

    Time frame: 30 days

  3. Mean number of days with mild overall respiratory symptoms

    Time frame: 30 days

  4. Time to symptom reduction

    Time frame: 30 days

  5. Time to elimination of symptoms

    Time frame: 30 days

  6. Average number of days with mild respiratory symptoms

    Time frame: 30 days

  7. Oxygen saturation

    Time frame: 30 days

  8. Hospitalization rate

    Time frame: 30 days

  9. Mortality

    Time frame: 30 days

07

Study locations

2 sites
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Dr. Michael Zahavi
    Oshawa, Ontario L1H1G6, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Jul 2021, 10 months after the start.

Of 138 industry-sponsored interventional studies with no phase under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 10 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 5, 2020
StartActual
Sep 2, 2020
Primary completionEst.
Jul 30, 2021
CompletionEst.
Sep 30, 2021
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04418505
Lead sponsor
Vielight Inc.
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Sep 2, 2020
Primary completion
Jul 30, 2021 (estimated)
Completion
Sep 30, 2021 (estimated)
Last update
Jun 14, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion